Andrew (“Drew”) E. Senyei, M.D. is a physician, venture capitalist, and inventor with more than 30 years of experience in the building of emerging technology and healthcare companies.

He served as Managing Director of Enterprise Partners Venture Capital for more than 25 years with U.S.$1.1 billion under management. He was the founding investor of multiple healthcare technology companies, including Nuvasive, one of the largest minimally non-invasive orthopedic companies in the U.S. with revenues in excess of U.S.$1 billion.

Senyei has served on the boards of more than 30 private and public companies. He is currently Chairman and CEO of NoniGenex, Inc., a company focused on whole population level testing for high-impact diseases using next generation automation technologies. He remains actively involved with early stage angel investing in a variety of high-tech industries in the U.S. as well as in China and is a senior advisor to Healthpoint Capital, a private equity firm.

He currently serves on The Board of Trustees at Northwestern University, where he chairs the Medicine Committee. He is also a member of the UC San Diego Foundation board and a founding member of the UCSD 21st Century China Leadership Board. He is co-chair of the advisory board of the California Institute for Telecommunications and Information Technology (Calit2) and is a former Chair of the UCSD Jacobs School of Engineering Advisory Council.

Senyei was named one of the Top 100 Venture Capitalists in the U.S. on Forbes magazine's 2006 Midas Touch List and he was the recipient of the 2007 Ernst & Young San Diego Master Entrepreneur Award.

Senyei received his M.D. from Northwestern University and completed his residency training at the University of California, Irvine, where he served on the faculty prior to becoming active full-time with venture capital funding of early stage technology companies.

Last Updated: November 17, 2020



How Can the U.S. Maintain Global Leadership in Science and Technology?

Susan Shirk, Helen Toner & more
Among the central issues the incoming U.S. presidential administration will face as it formulates policy toward China is the interconnectedness between the two countries in the spheres of science and technology. U.S. concerns over national security...